Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-01-11
2002-06-11
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S012200, C514S013800, C514S015800, C514S054000, C514S062000, C514S440000, C435S069500, C435S325000, C435S320100, C435S069300, C536S023500, C536S023400, C536S023100, C530S350000, C530S300000, C424S085100, C600S009000
Reexamination Certificate
active
06403553
ABSTRACT:
The present invention relates to the use of polypeptides of the MIP (macrophage inflammatory proteins) class for the treatment of diseases involving a pathological reduction of thrombocytopoiesis.
Thrombocytes (platelets) play a key role in blood clotting and wound healing. Therefore, thrombocytic diseases can lead to hemostatic disorders and thus to massive hemorrhages. It is generally distinguished between thrombocytopenias, in which the platelet count is reduced, and thrombocytic dysfunctions, in which the function of platelets is impaired, in spite of normal counts.
Possible causes of thrombocytopenia include reduced or lacking megakaryocytes in the bone marrow, reduced platelet production, sequestration of platelets in the spleen, increased thrombocytolysis, increased platelet consumption or dilution of the platelet pool. Irrespective of the etiology, severe thrombocytopenia results in skin hemorrhages in the form of multiple petechiae, which are usually most pronounced at the lower legs, and isolated little ecchymoses following trivial traumata. More serious are mucosal hemorrhages (nosebleeding; bleedings in the gastrointestinal tract, in the urogenital tract and in the vagina) and bleedings following surgical interventions. Depending on the extent of thrombocytopenia, severe gastrointestinal bleedings and bleedings into the central nervous system with life-threatening consequences can occur.
Thrombocytopenias can be observed in a variety of diseases and in certain therapeutic treatments. Reduced thrombocytopoiesis can occur as a result of, e.g., myelosuppressive therapy (irradiation, chemotherapy, especially high-dose therapy), bone marrow transplantation, leucemia, anemia (aplastic anemia, Fanconi's anemia etc.), or also following abuse of alcohol. Increased platelet consumption or thrombocytolysis can be the result of diseases such as idiopathic thrombocytopenic purpura, infections (thrombocytopenia upon HIV infection, sepsis etc.), immunological basic diseases (auto-immune diseases, such as systemic lupus erythematosus), chronical leucemia or malignant lymphomas. A reduced platelet count can also occur as a medicament-induced thrombocytopenia upon administration of, for example, heparin, quinidine, sulfonamides, oral antidiabetics, gold salts or rifampicin.
Within the scope of diagnostics in clinical chemistry, the determination of cell counts in the peripheral blood picture provides the essential parameters for establishing the extent of thrombocytopenia, and for obtaining first indications of possible causes. Thus, for example, an increased proportion of large platelets (determinable from a blood smear or by measuring the average platelet volume in an electronic blood cell analyzer) indicates a compensatorily increased platelet production. This is often found in secondary thrombocytopenias due to increased lysis or consumption of platelets. In severe thrombocytopenias from any cause, the bleeding time is prolonged. However, in patients with moderate thrombocytopenia (e.g., 50,000 platelets/&mgr;l), a determination of bleeding time can provide valuable information. In this case, a highly prolonged bleeding time indicates that antibody loading of the platelets evidently results in a functional disorder of the circulating platelets. Another diagnostic criterion is provided by examinations of bone marrow punctures. Thrombocytopenias can then be evaluated by the number and appearance of the megakaryocytes.
For a treatment of thrombocytopenias, the primary causes must be recognized and corrected, e.g., in medicament-induced thrombocytopenias, by a quick discontinuation of the medicament causing the thrombocytopenia, or through the recognition and treatment of an infection with endotoxin-producing Gram-negative germs. If the thrombocytopenia is the consequence of a megakaryopoietic disorder and thus a reduced production of platelets, e.g., following chemotherapy, the platelet count can mostly be increased for a period of 2-3 days by the administration of platelet concentrates. For treating thrombocytopenia, platelet concentrates are administered either continuously (1 to 2 units per hour) or in larger quantities in intervals of several hours, e.g., 6 to 8 units every 4 to 6 hours. For prophylaxis, however, platelet concentrates should be employed reservedly, since their effectivity can drop off upon repeated use because of the development of platelet allo-antibodies. Also, in transfusions, the risk of an infection must not be neglected. If a quick regeneration of the bone marrow function cannot be expected, platelet transfusion should be employed only for the treatment of a clinically manifest tendency to bleed. In thrombocytopenias due to increased platelet consumption, platelet transfusions should be given prophylactically only in exceptional cases, since the platelets are reeliminated from the circulation within one to several hours in such diseases. In the treatment of heparin-induced thrombocytopenia, transfused platelets may also result in the formation of platelet-fibrin thrombi and thus in severe thrombophilia.
Polypeptides of the MIP (macrophage inflammatory proteins) class are known from WO 95/17092. These polypeptides are secreted, for example, by macrophages or lymphocytes if they are stimulated by Gram-negative bacteria, lipopolysaccharides or concanavalin A. WO 95/17092 describes such polypeptides and their use for the preparation of medicaments for the treatment of infections, cancers, inflammations, myelopoietic dysfunctions or auto-immune diseases. In particular, in connection with hematopoiesis, the inhibition of bone marrow stem cells by MIPs is described, for example, for treating myeloproliferative diseases. The inhibitory effect of MIPs on stem cell proliferation is also described as a therapeutic principle in the treatment of cancer, for tranquilizing stem cells by a preliminary MIP administration and thus protecting them from the side-effects of chemotherapy. In addition, WO 95/17092 describes inhibitors and antagonists of such polypeptides which are intended to neutralize MIP-caused bone marrow suppression and thus to be employed for the treatment of, e.g., aplastic anemia or myelodysplastic syndrome. A treatment of thrombocytosis by the administration of MIPs is to be achieved by increasing the vascular permeability in the periphery and thus increased sequestration of platelets. In a recently released meeting abstract, it is reported that the maturation of progenitor cells of monocytes/macrophages is inhibited in the presence of MIP 1&ggr;, an MIP which is known from WO 95/17092. Consequently, MIP 1&ggr; is designated as an M-CIF (macrophage colony inhibition factor).
Further, another MIP fragment with the designation of HCC-1 is known from DE 43 44 387. This fragment is a polypeptide which comprises the sequence of MIP-3 (1-69), N-terminally extended by five additional amino acids. This peptide is therapeutically employed for the treatment of disorders in the migration of cells, diseases of the immune system, tumors, and dysfunction of regulatory growth factors.
From WO 97/06871, it is known that an enhanced regeneration of the hematopoietic system in connection with myelosuppressive therapy can be achieved by the continuous administration of stem cell chemokines (SCC). As stem cell chemokines, there are mentioned, for example, the proteins LD78 (huMIP-1&agr;), muMIP-1&agr;, MIP-1&bgr;, IL-8, GRO, NAP-2, MCAF, ENA78, PF4, GCP-2, INPROL, MCP-1, MCP-2 and MCP-3 and their analogues. The regeneration of the hematopoietic system is defined as being satisfactory when the counts of neutrophiles, platelets and/or progenitor cells have increased to a range of more than 25% of their normal values. However, the administration of the stem cell chemokines is described only in connection with myelosuppressive therapy (MT), especially before starting the MT, during the MT and immediately after the MT.
In WO 96/19234, the combined use of CxC chemokines and of hematopoiesis-stimulating agents, such as CSFs, for enhancing the release and mobilization of he
Forssmann Wolf-Georg
Opitz Hans-Georg
Schmitt Joachim
Schultz-Knappe Peter
Arent Fox Kintner Plotkin & Kahn
Carlson Karen Cochrane
Forssmann Wolf-Georg
Robinson Hope A.
LandOfFree
Use of polypeptides for treating thrombocytopenia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of polypeptides for treating thrombocytopenia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of polypeptides for treating thrombocytopenia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2947052